163 related articles for article (PubMed ID: 32001801)
1. Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemia.
Wethmar K; Matern S; Eßeling E; Angenendt L; Pfeifer H; Brüggemann M; Stelmach P; Call S; Albring JC; Mikesch JH; Reicherts C; Groth C; Schliemann C; Berdel WE; Lenz G; Stelljes M
Bone Marrow Transplant; 2020 Jul; 55(7):1410-1420. PubMed ID: 32001801
[TBL] [Abstract][Full Text] [Related]
2. Prognosis of patients with acute lymphoblastic leukaemia relapsing after allogeneic stem cell transplantation.
Ferra Coll C; Morgades de la Fe M; Prieto García L; Vaz CP; Heras Fernando MI; Bailen Almorox R; Garcia-Cadenas I; Calabuig Muñoz M; Ripa TZ; Zanabili Al-Sibai J; Novoa S; Aguado B; Torrent Catarineu A; López-Godino O; Martino Bofarull R; Kwon M; Campos Júnior A; Caballero Barrigón D; Ribera Santasusana JM
Eur J Haematol; 2023 Jun; 110(6):659-668. PubMed ID: 36813736
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
4. Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.
Uzunel M; Jaksch M; Mattsson J; Ringdén O
Br J Haematol; 2003 Sep; 122(5):788-94. PubMed ID: 12930390
[TBL] [Abstract][Full Text] [Related]
5. Pre- and post-transplant minimal residual disease predicts relapse occurrence in children with acute lymphoblastic leukaemia.
Lovisa F; Zecca M; Rossi B; Campeggio M; Magrin E; Giarin E; Buldini B; Songia S; Cazzaniga G; Mina T; Acquafredda G; Quarello P; Locatelli F; Fagioli F; Basso G
Br J Haematol; 2018 Mar; 180(5):680-693. PubMed ID: 29359790
[TBL] [Abstract][Full Text] [Related]
6. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
[TBL] [Abstract][Full Text] [Related]
7. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
8. Comparison of chimerism and minimal residual disease monitoring for relapse prediction after allogeneic stem cell transplantation for adult acute lymphoblastic leukemia.
Terwey TH; Hemmati PG; Nagy M; Pfeifer H; Gökbuget N; Brüggemann M; Le Duc TM; le Coutre P; Dörken B; Arnold R
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1522-9. PubMed ID: 24907626
[TBL] [Abstract][Full Text] [Related]
9. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
10. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia.
Chen CT; Gau JP; Liu JH; Chiou TJ; Hsiao LT; Liu YC
J Chin Med Assoc; 2018 Dec; 81(12):1038-1043. PubMed ID: 30100353
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
[TBL] [Abstract][Full Text] [Related]
12. Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Jabbour E; Short NJ; Jorgensen JL; Yilmaz M; Ravandi F; Wang SA; Thomas DA; Khoury J; Champlin RE; Khouri I; Kebriaei P; O'Brien SM; Garcia-Manero G; Cortes JE; Sasaki K; Dinardo CD; Kadia TM; Jain N; Konopleva M; Garris R; Kantarjian HM
Cancer; 2017 Jan; 123(2):294-302. PubMed ID: 27602508
[TBL] [Abstract][Full Text] [Related]
13. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Balduzzi A; Di Maio L; Silvestri D; Songia S; Bonanomi S; Rovelli A; Conter V; Biondi A; Cazzaniga G; Valsecchi MG
Br J Haematol; 2014 Feb; 164(3):396-408. PubMed ID: 24422724
[TBL] [Abstract][Full Text] [Related]
15. Influence of pre-transplant minimal residual disease on prognosis after Allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis.
Shen Z; Gu X; Mao W; Yin L; Yang L; Zhang Z; Liu K; Wang L; Huang Y
BMC Cancer; 2018 Jul; 18(1):755. PubMed ID: 30037340
[TBL] [Abstract][Full Text] [Related]
16. Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation.
Mannis GN; Martin TG; Damon LE; Andreadis C; Olin RL; Kong KA; Faham M; Hwang J; Ai WZ; Gaensler KML; Sayre PH; Wolf JL; Logan AC
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1030-1036. PubMed ID: 26899561
[TBL] [Abstract][Full Text] [Related]
17. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease prior to stem cell transplant for childhood acute lymphoblastic leukaemia.
Goulden N; Bader P; Van Der Velden V; Moppett J; Schilham M; Masden HO; Krejci O; Kreyenberg H; Lankester A; Révész T; Klingebiel T; Van Dongen J
Br J Haematol; 2003 Jul; 122(1):24-9. PubMed ID: 12823342
[TBL] [Abstract][Full Text] [Related]
19. Pre-Emptive Immunotherapy for Clearance of Molecular Disease in Childhood Acute Lymphoblastic Leukemia after Transplantation.
Rettinger E; Merker M; Salzmann-Manrique E; Kreyenberg H; Krenn T; Dürken M; Faber J; Huenecke S; Cappel C; Bremm M; Willasch A; Bakhtiar S; Jarisch A; Soerensen J; Klingebiel T; Bader P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):87-95. PubMed ID: 27742575
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease.
Shah S; Martin A; Turner M; Cong Z; Zaman F; Stein A
Leuk Lymphoma; 2020 May; 61(5):1052-1062. PubMed ID: 31960716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
